A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations

Bibliographic Details
Main Authors:	Pingli Wang, Liming Cao, Panwen Tian, Shengxiang Ren, Liyun Miao, Chengzhi Zhou, Yun Fan, Yuping Li, Dongqing Lv, Xin Zhao, Mei Yang, Chaonan Zhu, Bing Yu, June Xu, Yong Song, Kai Wang
Format:	Article
Language:	English
Published:	Wiley 2023-09-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12456

Internet

https://doi.org/10.1002/cac2.12456